Review Article

Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2

C. Romei, E. Pardi, F. Cetani, and R. Elisei

Department of Endocrinology and Metabolism, University of Pisa, 56124 Pisa, Italy

Correspondence should be addressed to R. Elisei, rossella.elisei@med.unipi.it

Received 30 July 2012; Accepted 16 September 2012

Copyright © 2012 C. Romei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Multiple endocrine neoplasia (MEN) are clinical inherited syndromes affecting different endocrine glands. Three different patterns of MEN syndromes can occur (MEN 1, MEN 2A, and MEN 2B). MEN syndromes are very rare, affect all ages and both sexes are equally affected. MEN 1 is characterized by the neoplastic transformation of the parathyroid glands, pancreatic islets, anterior pituitary, and gastrointestinal tract. Heterozygous MEN 1 germline mutations have been detected in about 70–80% of patients with MEN 1. The mutations are scattered throughout the entire genomic sequence of the gene. MEN 1 patients are characterized by variable clinical features, thus suggesting the lack of a genotype-phenotype correlation. Therapeutical approaches are different according to the different endocrinopathies. The prognosis is generally good if adequate treatment is provided. In MEN 2 syndromes, the medullary thyroid cancer (MTC) is almost invariably present and can be associated with pheochromocytoma (PHEO) and/or multiple adenomatosis of parathyroid glands with hyperparathyroidism (PHPT). The different combination of the endocrine neoplasia gives origin to 3 syndromes: MEN 2A, MEN 2B, and FMTC. The clinical course of MTC varies considerably in the three syndromes. It is very aggressive in MEN 2B, almost indolent in the majority of patients with FMTC and with variable degrees of aggressiveness in patients with MEN 2A. Activating germline point mutations of the RET protooncogene are present in 98% of MEN 2 families. A strong genotype-phenotype correlation has been observed and a specific RET mutation may be responsible for a more or less aggressive clinical course. The treatment of choice for primary MTC is total thyroidectomy with central neck lymph nodes dissection. Nevertheless, 30% of MTC patients, especially in MEN 2B and 2A, are not cured by surgery. Recently, developed molecular therapeutics that target the RET pathway have shown very promising activity in clinical trials of patients with advanced MTC. MEN 2 prognosis is strictly dependent on the MTC aggressiveness and thus on the success of the initial treatment.

1. Introduction

The term multiple endocrine neoplasia (MEN) defines clinical inherited syndromes affecting different endocrine glands, each with its own characteristic pattern [1, 2]. In some cases, the tumors are malignant, in others, benign. Benign or malignant tumors of nonendocrine tissues occur as components of some of these tumor syndromes.

Three different patterns of MEN syndromes can occur (MEN 1, MEN 2A, and MEN 2B) with some new variants such as MEN 4, which is considered a variant of MEN 1 and the familial medullary thyroid cancer (FMTC), which is considered a variant of MEN 2A [3, 4]. These syndromes are familial and caused by inherited genetic mutations, which have been discovered within the last 20 years [5].

2. Multiple Endocrine Neoplasia Type 1

2.1. Definition. Multiple endocrine neoplasia type 1 syndrome (MEN 1, OMIM no. 131100), also known as Wermer’s syndrome because of the description in 1954 by Dr. Paul Wermer of a pluriglandular dysfunction transmitted as a dominant trait, is characterized by simultaneous neoplastic transformation of multiple endocrine tissues, typically the parathyroid glands, pancreatic islets, and anterior pituitary. The case of an acromegalic patient with three enlarged parathyroid glands and a pituitary adenoma was indeed firstly described in 1903 and, after small case reports, Underdahl, Woolner and Black in 1953 described a series of 8 patients with various combinations of pituitary, parathyroid, and pancreatic islet adenomas [6].
This disorder is strongly suspected either in patients with endocrinopathies of at least 2 of the 3 main affected glands (i.e., parathyroid, enteropancreatic, and pituitary tumors) or in patients with at least one endocrinopathy in one of these organs and a first-degree relative who is affected by one of these tumors (familial MEN 1). Patients with features of MEN 1 syndrome but without a family history of MEN 1 are affected by a sporadic form of MEN 1. MEN 1 syndrome presents a wide spectrum of more than 20 endocrine and nonendocrine associated manifestations other than the classic endocrinopathies, including adrenocortical, gastric, thymic or bronchial tumors, foregut carcinoids, visceral and cutaneous lipomas, meningiomas, facial angiofibromas, concurring to different phenotypic presentations (Figure 1) [7–9]. Thyroid tumors are also frequently associated, but this association should be considered likely casual for the high incidence of thyroid abnormalities in the general population. Various clinical cases report rare combinations of less common tumors of MEN 1 and these atypical cases are also known as MEN 1 “phenocopy variants.”

The most frequent MEN 1-associated endocrinopathy, occurring in nearly 100% of patients by the age of 50 yrs, is primary hyperparathyroidism (PHPT), characterized by the synchronous or asynchronous development of multiglandular parathyroid hyperplasia with a benign course, while extremely rare is the occurrence of parathyroid carcinoma (PC), being only six cases of PC associated with MEN 1 in the literature [10]. Tumors of the parathyroid are often the first manifestation of MEN 1 in more than 85% of patients, with a typical age of onset of 20–25 yrs [11–13].

Gastroenteropancreatic endocrine (GEP) tumors, most arising in the pancreas as nonfunctioning neuroendocrine tumours or insulinomas, develop in up to 70–80% of MEN 1 patients, and gastrinoma represents, together with foregut carcinoids, the major cause of morbidity and mortality in MEN 1, because of its high rate of metastasis [17, 18] (Figure 1). The lesions range from microadenomas to macroadenomas, and to metastatic carcinomas. These tumors arise after the age of 40 yrs. Gastrinomas account for more than 50% of all GEP tumors and are typically small (<5 mm), multiple, mainly located in the duodenum and rarely in the pancreas. In the latter case it is difficult to distinguish these lesions from concomitant nonfunctioning pancreatic tumors (NFPTs).

The prevalence of pituitary tumors in MEN 1 ranges between 10% and 60%, being the prolactinoma the commonest MEN 1-related pituitary adenoma, although other pituitary tumors have been described so far (Figure 1). The majority of tumors are microadenomas (<10 mm). The mean age ± SD of onset has been reported to be 38 ± 15 yrs. Pituitary tumors are generally more invasive, symptomatic, with a higher prevalence of macroadenomas and a worse response to treatment than the sporadic counterparts [19, 20].

Foregut carcinoids, especially of the lung and thymus, are generally aggressive tumors and associated with a very high lethality. Adrenal tumors follow a benign course in most MEN 1 cases, and the majority are bilateral, hyperplastic, and nonfunctional [21]. Lipomas, both cutaneous and visceral, are present in about one-third of MEN 1 patients. Multiple facial angiofibromas occur in 40–80% of MEN 1 patients. Collagenomas are also common. These cutaneous lesions may be helpful for presymptomatic diagnosis of MEN 1 carriers.

2.2. Epidemiology. MEN 1 is rare, occurring in about one of 30,000 individuals, with an estimated prevalence of 2-3 per 100,000. The disorder affects all ages with a range of 5–81 yrs and both sexes equally [22]. A recent multicenter study analyzed 734 cases of MEN 1 and reported a different phenotype expression of the MEN 1 disease between males and females, in particular the prevalence of pancreatic tumors was higher in males than in females, while the opposite happened for the pituitary tumors. Thymic tumors were exclusively found in men. There was no significant gender difference in the prevalence and the probability of developing PHPT, adrenal and bronchial tumors in contrast to sporadic counterparts or in the proportion of positive genetic tests [23].

MEN 1-affected patients do not belong to particular geographical area, and there are no racial or ethnic preferences. No risk factors are known.

2.3. Pathogenesis. In 1988, linkage analysis studies in affected families placed the MEN 1 gene within a 2 Mb interval in 11q13 and subsequently loss of heterozygosity [24] studies narrowed the location of the gene to a 600 kb interval [25]. The candidate gene, MEN 1, was finally identified by positional cloning in 1997 [26]. Combined LOH studies by microsatellite analysis in tumor tissues of MEN 1 patients and pedigree studies of large kindred supported a tumor suppressor function of the MEN 1 gene suggesting the mechanism of biallelic inactivation firstly described by Knudson for the gene of retinoblastoma [27].

The MEN 1 gene consists of 10 exons, the first of which is untranslated, spanning 7.2 kb of genomic sequence and encoding a protein, menin, of 610 amino acids, that does not present homologies to any other known proteins. MEN 1 mRNA is expressed at a similar level in endocrine and noneendocrine organs, leaving unexplained the basis for endocrine predominance of neoplasia. Menin is a nuclear protein whose binding to the AP1 transcription factor JunD suggests a role in transcriptional regulation. The interaction with several partners and its participation in a variety of mechanisms, including regulation of cell proliferation and differentiation, apoptosis, endocrine/metabolic functions and the maintenance of genomic stability by DNA repair, have been so far reported [28]. The tumor suppressor nature of MEN 1 gene is best achieved by menin-mediated inhibition of cell proliferation through multiple mechanisms such as (a) the interaction of menin with histone-modifying enzymes (MLL, EZH2, and HDACs) that affect gene transcription; (b) the interaction with various transcription factors, such as JunD, NF-κB, PPARγ, and VDR, to induce or suppress gene transcription; (c) the inhibition of cellular proliferation via TGF-β signaling and Wnt/β-catenin signaling pathways; (d) the repression of pro-proliferative factors (IGFBP-2, IGF2s
Figure 1: Prevalence of MEN 1 endocrine and nonendocrine manifestations. * Data obtained by a study on a series of 74 patients with MEN1 [8] and on a study determining the frequency of skin lesions in a series of 32 patients with MEN1 [9] Abbreviations: VIPoma, vasoactive intestinal peptide secreting tumor; PRLoma, prolactin secreting tumor; GHoma, growth hormone secreting tumor; ACTH-oma, adrenocorticotropic hormone secreting tumor; ECLoma, enterochromaffin-like tumour.

and PTHrP) involved in endocrine tumors; (e) the direct effect on cell cycle progression (Figure 2) [29]. The recent described crystal structure of the human menin should help us to better explain the opposite effects of the protein in the transcription process [30].

Heterozygous MEN 1 germline mutations have been detected in about 70–80% and 30% in patients with familial and sporadic MEN 1, respectively. The mutations are scattered throughout the entire genomic sequence of the gene, consistent with the lack of mutational hot spots. More than 1336 different germline and sporadic MEN 1 gene mutations have been reported so far from the cloning of the gene [31]. More than 70% of MEN 1 mutations lead to truncated form of the protein, confirming a loss-of-function mechanism.

To date, murine models of MEN 1 syndrome have been generated by disrupting different parts of the murine MEN 1 gene localized on chromosome 19. The homozygous status shows a lethal phenotype at embryonic level, while the heterozygous mutant mice have a phenotype similar to the human MEN 1 disease, with a survival rate significantly lower than the wild-type mice, and with pancreatic islet lesions ranging from hyperplasia to insulin-producing islet cell tumors as the first manifestation [32]. Lesions of the parathyroid, pituitary, and adrenal glands occur later, and in addition to the typical MEN 1-associated endocrine tumors, these mice also develop tumors of the gonads and the thyroid. All the major tumors typically exhibit multistage tumor progression with metastatic potential [33, 34].

The variable clinical expression between MEN 1 patients and relatives of the same family sharing the same genetic defect suggests the lack of a genotype-phenotype correlation (Figure 3) [35]. The lack of a correlation between the genetic status and the phenotypic expression could be due to either additional genetic events or epigenetic factors. A variant of the classic MEN 1 syndrome, known as MEN 1-Burin or “prolactinoma variant” of MEN 1, has a characteristic phenotype, such as an unusual higher incidence of carcinoid and pituitary tumors, all prolactinomas, a very low incidence of pancreatic endocrine tumors, and a late onset PHPT compared with families with typical MEN 1. Initially four large MEN 1-Burin kindreds were identified in the Canadian Newfoundland area and share a common nonsense mutation in the MEN 1 gene, suggesting the existence of a founder mutation [36]. Following the original report, similar families have also been described in Japan, Brazil, USA, and Mauritius carrying different nonsense or frameshift mutations suggesting that there is not a common MEN 1 mutation in all MEN 1-Burin families [37, 38]. In addition, some kindreds may develop only PHPT, and this condition is referred to as familial isolated hyperparathyroidism (FIHP). Up to date mutations of the MEN 1 gene, mostly missense, have been detected in 42 FIHP families [24, 39].
2.4. Diagnosis. A clinical diagnosis of MEN 1 is made in individuals who have developed two or more of the classic MEN 1-associated tumors and in patients who have one classic MEN 1-related tumor and a family history of MEN 1. The biochemical diagnosis of PHPT, prolactinoma, and secreting endocrine tumors of the GEP tract in known or suspected MEN 1 is the same as for sporadic tumors (Table 1). Presymptomatic MEN 1 is biochemically detectable virtually one-two decades prior to full-blown phenotype, when symptoms are often related with the hormone hypersecretion or mass effect due to the growth of the tumor. Imaging studies on PHPT do not influence the indications for surgery [44]. Magnetic resonance imaging (MRI) is the test of choice for pituitary tumors [45]. Computed tomography (CT) and MRI are sensitive to detecting pancreatic endocrine tumors, adrenal, thymic, and lung carcinoids. Esophagogastroduodenoscopy with biopsy is recommended in patients with hypergastrinemia to detect peptic ulcer disease and carcinoids. In asymptomatic patients with MEN 1 endoscopic ultrasound (EUS) study is the most sensitive procedure to detect small (≤10 mm) pancreatic lesions [46]. For the identification of metastases of pancreatic tumors, the procedure of choice is the somatostatin receptor
scintigraphy. The imaging test schedule of MEN 1-affected patients is summarized in Table 1 [3, 47].

2.4.1. Genetic Testing. Mutation analysis of the MEN 1 gene may be used to confirm the clinical diagnosis, provide a genetic diagnosis in difficult cases, and screen asymptomatic relatives. The genetic testing of asymptomatic family members should be offered in early childhood since the first MEN 1 manifestations may occur by the age of 5 yrs [48]. MEN 1 germline mutation testing should be offered to relatives of MEN 1 patients before biochemical and imaging screening examinations in order to exclude MEN 1 tumors. MEN 1 gene testing can be helpful when clinical diagnosis is inconclusive; however, but a suspicion of MEN 1 exists. The genetic analysis of the entire coding region and splice sites fails to detect MEN 1 mutation in about 30% of typical MEN 1 kindred. If MEN 1 mutation is not detected, testing for large gene deletions, haplotype analysis of MEN 1 locus, or analysis of other genes should be considered [47].

2.4.2. Screening Program of Tumor Expression in MEN 1 Gene Carriers. In contrast to the clinical importance of RET sequence testing in MEN 2, presymptomatic gene diagnosis has not been established to improve morbidity and mortality in MEN 1. Clinical practice guidelines on the management of MEN 1 gene carriers who have not yet developed the disease have recently been published [47]. Briefly, annual biochemical screening should include the following measurements.

(i) PHPT: intact PTH and albumin-corrected total serum calcium or ionized serum calcium by age 8.
(ii) Pituitary tumors: serum prolactin and insulin growth factor 1 (IGF-1) by age 5.
(iii) Insulinoma: serum fasting glucose and insulin by age 5.
(iv) Gastrinoma: gastrin, gastric acid output, and secretin-stimulated gastrin.
(v) Other GEP tumors: proinsulin, glucagon, and plasma chromogranin A before the age of 10 yrs. Biochemical tests for adrenal lesions are not recommended unless the presence of symptoms or signs of functioning tumors and/or the detection of tumors with a diameter >10 mm on imaging.

Diagnostic imaging procedures are recommended for the identification of pituitary tumors (MRI every 3 yrs), GEP
Table 1: Biochemical and imaging screening for tumors in MEN 1 patients.

| Tumor                  | Annual biochemical tests                                                                 | Imaging tests                                         |
|------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------|
| Parathyroid            | Calcium, PTH                                                                            | MRI, CT, and endoscopic ultrasound (annually),       |
| GEP                    | Gastrin, glucagon, vasointestinal polypeptide, pancreatic polypeptide, chromogranin A, insulin, fasting glucose | gastroscopy with biopsy every 3 yr in patients with hypergastrinemia |
| Pituitary              | PRL, IgF1                                                                                | MRI (every 3–5 yrs)                                  |
| Adrenal                | —                                                                                       | CT or MRI (every 3 yrs)                              |
| Thymus and lung        | —                                                                                       | CT or MRI (every 1–2 yrs)                            |

*Biochemical test should be performed in patients with tumors greater than 1 cm or with clinical features.

2.5. Therapy

2.5.1. PHPT. The optimal surgical approach is controversial. Approaches include either subtotal parathyroidectomy (PTx) (removal of 7/8 of the parathyroid tissue) with cryopreservation of parathyroid tissue, or total PTx and autologous parathyroid tissue graft in the forearm [49, 50].

At initial surgery, transcervical near total thymectomy is also recommended [3] since it may cure thymic carcinoids or prevent their development; in addition, the thymus is a common site for parathyroid tumors in MEN 1 patients with recurrent PHPT. Minimally invasive PTx is usually not recommended for the typical multiglandular involvement. Involvement of a highly experienced surgeon is crucial to optimal outcome. There are reports showing that the recurrence rate of PHPT in MEN 1 for procedures less than subtotal PTx were 8%, 31%, and 63% at 1, 5, and 10 years, respectively [51]. However, when subtotal or total PTx was performed, the rate of recurrence was 5%, 20%, and 39% at 1, 5, and 10 years, respectively. Rapid intraoperative PTH (iPTH) measurement can be helpful to prevent a persistent PHPT after glands removal [52]. Total PTx guided by iPTH monitoring and followed by autograft to the forearm led to a 10% of recurrences in the autografted parathyroid after a mean time of years after surgery [53].

2.5.2. GEP Tumors

Gastrinoma. The therapy in MEN 1-associated gastrinoma aims for the treatment of acid hypersecretion and the resection of the tumor [54]. However, surgical versus nonsurgical management of gastrinoma in MEN 1 syndrome is still controversial since successful outcome of surgery is rare. When surgery is not possible, the medical treatment may include somatostatin analogs, interferon-alpha, and chemotherapy. Proton pump inhibitors or H2-receptor blockers are able to reduce gastric acid output in these patients.

Other GEP Tumors. The surgical approach for asymptomatic NFPT in MEN 1 is controversial. The choice between preserving pancreatic-duodenectomy or a more aggressive approach depends on the estimated risk for the development of metastatic disease, the size of the lesions, and the functioning nature of the tumour [55]. Surgery is usually indicated for insulinoma. Somatostatin analogs, radionuclide therapy, biotherapy, and chemotherapy may be used in inoperable tumors [47]. In cases of inoperable or metastatic well-differentiated tumors, sunitinib or everolimus may be considered [56].

2.5.3. Pituitary Tumors. Treatment of pituitary tumors in MEN 1 is identical to that in sporadic tumors. Dopamine agonists, especially cabergoline, are the preferred treatment of PRL-secreting tumors. Transsphenoidal surgery is the treatment of choice in GH-secreting tumors with a success rate of 50–70%. Somatostatin analogs (octreotide and lanreotide) are considered the current medical treatment of choice of GH-secreting tumors and are able to normalize the serum levels of GH and IgF1 in ≥50% of patients. Dopamine agonists can be used in mixed GH-PRL secreting tumors and in cases of tumors resistant to somatostatin analogs. Surgery is the treatment of choice in ACTH-secreting pituitary tumors. Radiation therapy can be used in cases of persistent or recurrent disease.

2.5.4. Adrenal Tumors. Treatment of adrenal tumors in MEN 1 is similar to that for sporadic tumor. Surgery is the treatment of choice in functioning tumors and nonfunctioning tumors with significant growth over a 6-month interval, suspicious radiological features, and greater than 4 cm in size [57].

2.5.5. Thymic, Lung, and Gastric Neuroendocrine Tumors. The treatment of choice for thymic and lung carcinoids is surgery. When surgery is not possible, chemotherapy and radiotherapy should be considered.

The optimal therapy of gastric carcinoids is controversial. Endoscopic excision or partial total gastrectomy is required for tumors >10 mm. Lesions <10 mm can be monitored by endoscopy [47].

2.6. Prognosis. The prognosis is generally good if adequate treatment is provided for parathyroid, pancreatic, and pituitary tumors. Pancreatic endocrine tumours associated with MEN 1 are less malignant than sporadic tumors and
carry a better prognosis, with a median survival of 15 years compared to 5 years for patients with sporadic tumors. This may reflect more indolent disease or earlier diagnosis [58].

3. Multiple Endocrine Neoplasia Type 2

3.1. Definition. Multiple endocrine neoplasia type 2 syndrome (MEN 2) is characterized by the association of benign and malignant endocrine neoplasia with other nonendocrine diseases. In all syndromes, the medullary thyroid cancer (MTC), originating from C cells is present and can be associated with pheochromocytoma (PHEO) and/or multiple adenomatosis of parathyroid glands with hyperparathyroidism (PHPT). The different combination of the endocrine neoplasia with or without nonendocrine diseases gives origin to 3 different syndromes: MEN 2A, MEN 2B, and FMTC, this latter being considered as a variant of MEN 2A.

Although MEN 2 was firstly detected in the 19th century at the University Hospital of Freiburg, Germany [59], the association of an MTC and an PHEO in a single patient (Sipple's syndrome) was firstly described in 1961 [60, 61]. However, the entire entity of MEN 2A was recognized only in 1968 in a family with PHEO, MTC, PHPT, and Cushing’s disease [62].

MEN 2A (OMIM 171400) syndrome is the most common form. Almost all affected patients develop MTC which is usually multifocal, bilateral and almost invariably associated with C-cells hyperplasia. Fifty percent of MEN 2A patients are at risk of developing PHEO which, although frequently asynchronous, is usually involving both adrenal glands. About 25% of MEN 2A patients can also develop PHPT [63]. MTC is generally the first manifestation of MEN2A and develops between the ages of 5 to 25 years [16]. PHEO usually presents after MTC or concomitantly; however, it has been reported as the first sign of the syndrome in 13–27% of MEN 2A cases [64, 65]. In some cases, Hirschprung’s disease (HSCR) [66, 67], a congenital disease characterized by the aganglionicosis of the gut and/or cutaneous lichen amyloidosis [68–70], a pruritic lichenoid skin lesion usually located in the interscapular region, is associated with MEN 2A (Table 2).

MEN 2B syndrome (OMIM 162300) is the least common but the most aggressive form of MEN 2 (5–10% of all cases) [71]. Patients rarely become adults since the metastatic lesions of MTC develop and progress very rapidly. In MEN 2B patients, MTC is associated with PHEO in 45–50% of cases, while an association with PHPT was never described. Typically, almost 100% of MEN 2B patients develop mucosal neuromas, bumpy lips, ganglioneuromatosis of the gastrointestinal tract, and a Marfanoid habitus [72] (Table 2).

Familial MTC (FMTC; OMIM 155240) is considered the mildest variant of MEN 2 since in patients with FMTC there is a strong predisposition to develop MTC but a very low incidence of the other clinical manifestations of MEN 2A [73]. It has been diagnosed more frequently in recent years (35–40% of all cases), and particularly after the introduction of the genetic test [74, 75]. The clinical diagnosis of FMTC can only be posed when four or more family members across at least 2 or more generations have isolated MTC [3, 4, 68]. In the absence of these criteria, to prove that a subject has an FMTC, it is necessary to demonstrate the presence of a germline RET mutation [3]. Whereas MEN 2A and 2B are clinically very well defined, the lack of specific clinical features and/or familial history makes the diagnosis of FMTC relatively difficult, thus generating an underestimation of FMTC prevalence within families, especially in series where no genetic test for RET mutation has been performed. From the discovery of the first kindred affected by MTC, it was clear that these syndromes are inherited with an autosomal-dominant mendelian mechanism. For this reason, 50% of first-degree relatives of the index case (i.e., parents, siblings, and children) may be affected.

3.2. Epidemiology. MEN 2 syndrome is a very rare disease. To have a better idea of the rarity of the disease, one can consider that MEN 2 syndrome represents 25% of all MTC cases and that MTC represents only 5–10% of all thyroid malignancies, which represent only 1% of all human malignancies. Thus, the overall prevalence of MEN 2 syndromes is very low, accounting for about 0.02-0.03% of all human tumors. The total prevalence of all MEN2 variants has been estimated approximately 1/30,000 individuals [4].

The relative prevalence of the 3 syndromes reported in the first International RET consortium in 1994 [68] (Figure 4(a)) was significantly different from that reported in more recent studies [76] (Figure 4(b)). In particular, this change has been observed after the introduction of the RET genetic screening which allowed to recognize several cases of hidden FMTC.

3.3. Clinical Manifestation. The clinical appearance of MTC in MEN 2 syndromes is that of a thyroid nodular disease, similar to that of the sporadic form with the exception that it is usually bilateral, multicentric, and associated with C cell hyperplasia, which is considered a preneoplastic lesion. The clinical course of MTC varies considerably in the three syndromes. It is very aggressive and almost invariably unfavourable in MEN 2B, with affected patients rarely surviving after the adolescence. It is almost indolent in the majority of patients with the FMTC and shows variable degrees of aggressiveness in patients with MEN 2A. It is the only malignant tumor and the most severe disease of the syndrome so that in the majority of cases the prognosis of the disease is mainly related with the prognosis of the MTC.

An age-related progression to MTC has been described with younger age of onset for MEN 2B (youngest reported 0.6 year), older age for FMTC (usually adult age > 20 years), and intermediate age (starting from 1.5 years, but childhood age is the most prevalent) [16] (Table 3).

Up to 70% of MTC patients have already cervical lymph node metastases at the diagnosis [77] and this is an unfavorable prognostic factor for the cure of the disease. About 30%, mainly belonging to MEN 2B and, to a lesser extent, to MEN 2A, have already distant metastasis at the time of diagnosis and this is an unfavorable prognostic factor
Table 2: Prevalence of tumoral diseases in MEN 2 syndromes.

| Phenotype | MTC (%) | PHEO (%) | HPT (%) | Nonendocrinological associated pathologies (%) |
|-----------|---------|----------|---------|-----------------------------------------------|
| MEN 2A    | 95      | 50       | 25      | Cutaneous lichen amyloidosis (10%)             |
|           |         |          |         | Hirschsprung’s disease (2%)                   |
|           |         |          |         | Mucosal neuromas (100%)                        |
|           |         |          |         | Marfanoid habitus (100%)                       |
|           |         |          |         | Ganglioneuromatosis of the gastrointestinal tract (60%) |
| MEN 2B    | 95      | 50       |  |                                  |
| FMTC      | 100     |          |         | padded with a table or similar structure.      |

Figure 4: Prevalence rates of the three MEN 2 phenotypes in the International RET Consortium series (a) and in an Italian series (b). A higher prevalence of the FMTC phenotype was observed in the Italian series with respect to that reported by the International Consortium, which was based on cases collected up to 1994-1995.

3.1. Genetics. For the survival although they have a median survival of 5–10 years.

MTC is usually the first neoplastic manifestation in most MEN2 kindred because of its earlier and overall higher penetrance. With few exceptions, PHEO and PHPT are usually discovered few years after the MTC diagnosis. Both PHEO and PHPT are benign diseases, but, when present, they can severely affect the patient with severe hypertension or unexpected hypertensive crisis and hypercalcemia, respectively.

Both CLA and mucosal and/or corneal nerves neuromas associated with a Marfanoid habitus are strongly suggestive of MEN 2A or MEN 2B, respectively.

3.4. Pathogenesis. During the 80s, genetic linkage analysis localized the MEN 2 gene into the centromeric region of chromosome 10. In 1993, RET germline mutations were recognized as the causative molecular alterations in MEN 2 syndromes [78–80]. The RET protooncogene is a 21-exon gene and encodes for a tyrosine kinase transmembrane receptor located on chromosome 10q11.2. The receptor is composed of an extracellular domain (EC), with a distal cadherin-like region and a juxtamembrane cystein-rich region, a transmembrane domain (TM) and an intracellular domain with tyrosine-kinase activity (TK). In physiological conditions, the activation of the ret protein is secondary to its dimerization due to the interaction with one of its ligands. Four different ligands have so far been recognized: the glial cell-line derived neutrophilic factor (GDNF), neurturin (NTN), persepin (PNS) and artemin (ART). The interaction is mediated by a ligand-specific coreceptor (e.g., the GFRα-1 is the co-receptor for the GDNF). The dimerization of ret protein induces the autophosphorylation of the TK domain and the activation of downstream signaling pathways.

Activating germline point mutations of the RET protooncogene are causative events in MEN 2A, MEN 2B, and FMTC. RET mutations have been found to be widely distributed not only among the 5 cysteine codons 609, 611, 618, 620, and 634 but also in other noncysteine codons, such as codon 804 in exon 14, codon 883 in exon 15, and others. These widely spread non cysteine mutations are mainly associated with FMTC phenotype [74–76]. Virtually, all the mutations reported up to now...
Table 3: Age of onset of endocrine tumors according to RET Mutation MEN 2 database. Data from ARUP Scientific Resource for Research and Education.

| RET codon | MTC (years) | PHEO (years) | HPT (years) |
|-----------|------------|--------------|-------------|
| 533       | 21         | 34           |             |
| 609       | 4          | 19 (C609S)   | 38          |
| 611       | 6          | 30           | 40          |
| 618       | 5          | 19           | 41          |
| 620       | 5          | 19           |             |
| 630       | 1          | 32           |             |
| 634       | 0.8        | 5            | 10          |
| 768       | 9          | 59           |             |
| 790       | 10         | 28           |             |
| 791       | 15         | 38           |             |
| 804       | 6          | 28           | 9           |
| 883       | 10         |              |             |
| 891       | 9          | 46           | 17          |
| 918       | 0.17       | 12           |             |

are present on public databases (http://www.hgmd.cf.ac.uk; http://www.arup.utah.edu/database/MEN2). Their prevalence, which is clearly different in different countries [14–16], is reported in Table 4.

After the introduction of genetic screening in the diagnostic procedures of patients affected with apparently sporadic MTC, new mutations were found, especially in noncysteine-rich regions [74, 81, 82], that were mainly associated with FMTC [76]. Sometimes these new mutations are very rare, present only in a few families and a few family members, raising doubts as to whether they represent the driving force of the tumoral disease or result from the genetic screening associated with MTC [83, 84].

Apart from genetic alterations, no risk factors have been associated with the development of MEN 2 syndrome.

3.5. Genotype-Phenotype Correlation. The MEN 2 syndromes are characterized by a strong genotype-phenotype correlation and a specific RET mutation may be responsible for a particular phenotype and a more or less aggressive clinical course. This close association was firstly identified in an early study of 477 families affected with MEN 2 [68] and confirmed by several other studies. This correlation can be summarized as follows.

(a) approximately 98% of families with MEN 2A have a germline RET mutation in exon 10 or 11 [4, 68, 74]. Mutations at codon 634 (exon 11) is the most frequently found in typical MEN 2A families (87%): in this case the 3 endocrinopathies (i.e., MTC, PHEO and PHPT) are usually present both in the same subject and in several family members; mutations of cysteine residues at codons 609, 611, 618, and 620 are usually present in the other MEN 2A cases in which the combination of the 3 endocrinopathies is less common [4, 85, 86];

(b) germline RET mutations are found in approximately 95% of families with FMTC [76, 85]. These mutations are mainly affecting the non cysteine codons located at exons 5, 8, 13, 14 and 15 with 20% to 30% of mutations located at one of the five cysteine residues (codons 609, 611, 618, 620, and 634). A different geographic distribution has been reported especially for cysteine and non cysteine mutations [15, 16, 76] (Table 4);

(c) about 95% of individuals with the MEN 2B phenotype have a single point mutation in the tyrosine kinase domain of the RET gene at codon 918 in exon 16, which substitutes a threonine for methionine (M918T) [68]. Another mutation at codon 883 in exon 15, A883F, has been identified in several affected individuals without a M918T mutation. Tandem RET mutations of codons 805, 806, and 904 in cis configuration with the V804M mutation have also been reported in individuals with MEN 2B [87, 88]. Taken together, RET mutations have been found in more than 98% of individuals with MEN 2B.

The genotype-phenotype correlation clearly indicates that not all mutations confer the same aggressiveness to MTC. A similar evidence is for the different levels of disease penetrance. The American Thyroid Association recently categorized the RET mutations into four levels of risk (Table 5); these levels are of great usefulness for the identification of the therapeutic and follow-up strategies [4].

3.6. Genetic Testing. All patients affected by MTC, both those with a familial history of MEN 2 and those with an apparently sporadic form, must undergo a germline RET protooncogene analysis. The major reason to test apparently sporadic MTC is the evidence that 5–10% of these cases are indeed “hereditary” cases since they harbor a germline RET mutation [89].

When a germline mutation is found, all first-degree relatives should be submitted to RET analysis to distinguish “gene carriers” from “nongene carriers.” The RET gene carriers are at very high risk to develop MTC and they must be submitted to a diagnostic and therapeutic strategy which is very much conditioned by the ATA level of risk of the mutation. Recently, a greater importance has been recognized to serum calcitonin measurement for planning the timing of thyroidectomy which should be either prophylactic or very precocious when the tumor is still intrathyroid [90]. In nongene carriers the risk to develop MTC is similar to that of the general population and they should not be submitted to any further specific test.

The genetic screening activity should be accompanied by genetic counseling that should involve specific figures such as the geneticist, who will explain the particular type of transmissibility of the disease, the endocrinologist, who will explain the particular type of pathology and the risk of developing the different endocrine disorders, and possibly a psychologist to address issues arising from the knowledge of being a “gene carrier.”
Table 4: Different prevalence of RET germline mutations in hereditary MTC in different European countries.

| RET mutation | Italy (n = 246) [14] | Germany (n = 141) [15] | Euromen (n = 145) [16] |
|--------------|----------------------|------------------------|-----------------------|
| Cys634        | 86 (34.9%)           | 57 (40%)               | 98 (67.6%)            |
| Val804        | 52 (21.1%)           | 9 (6.4%)               | 3 (2.1%)              |
| Ser891        | 23 (9.3%)            | 3 (2.2%)               | 3 (2.1%)              |
| Met918        | 20 (8.1%)            | 21 (15%)               | 4 (2.8%)              |
| Cys618        | 15 (6.0%)            | 7 (5%)                 | 10 (6.9%)             |
| Glu768        | 9 (3.6%)             | 2 (1.4%)               | 1 (0.8%)              |
| Cys620        | 9 (3.6%)             | 10 (7%)                | 10 (6.9%)             |
| Leu790        | 8 (3.2%)             | 17 (12%)               | 7 (4.8%)              |
| Cys609        | 6 (2.4%)             | 1 (0.7%)               | 1 (0.8%)              |
| Cys630        | 4 (1.6%)             | 1 (0.7%)               | 1 (0.8%)              |
| Cys611        | 1 (0.4%)             | 2 (1.4%)               | 4 (2.8%)              |
| Tyr791        | 1 (0.4%)             | 10 (7%)                | 3 (2.1%)              |
| Ala883        | 1 (0.4%)             | 0                      | 0                     |
| Cys515        | 1 (0.4%)             | 0                      | 0                     |
| Lys666        | 1 (0.4%)             | 0                      | 0                     |
| Met848        | 1 (0.4%)             | 0                      | 0                     |
| Ser904        | 1 (0.4%)             | 0                      | 0                     |
| Thr338        | 1 (0.4%)             | 0                      | 0                     |
| Asp631        | 0                    | 1 (0.7%)               | 0                     |
| No mutations  | 6 (2.4%)             | 0                      | 0                     |

Table 5: Classification of RET mutations according to ATA risk level.

| ATA risk level | RET codons       |
|---------------|------------------|
| A (low)       | 768, 790, 791, 804, 649, 891 |
| B (medium)    | 609, 611, 618, 620, 630, 631 |
| C (high)      | 634              |
| D (highest)   | 918, 883         |

As stated above, the identification of the type of mutation also gives information about the possible phenotype suggesting the diagnostic and therapeutic strategy to be followed. Although all cases of hereditary MTC should be evaluated for the possibility of developing PHEO or PHPT, some of them are more likely to manifest these diseases while others will never develop them or in a late stage of the disease.

3.7. Clinical Diagnosis. Clinical evaluation of MEN 2 patients consists in the measurement of basal and/or pentagastrin-(Pg-) stimulated serum calcitonin (CT), neck ultrasound, and fine needle aspiration of thyroid nodule if present. To rule out the presence of an PHEO, an abdominal ultrasound should be performed accompanied by the measurement of both plasmatic and urinary epinephrine and norepinephrine; whenever possible, the measurement of metanephrines is better recommended for their higher sensitivity. Serum PTH, calcium, and vitamin D measurement should be always performed for the diagnosis of PHPT. The physical examination of these patients is also important particularly in MEN 2B syndrome because the phenotype is quite typical being characterized by Marfanoid habitus, mucosal and/or corneal nerves neurinomas. The presence of an itchy/dark spot in the interscapular region should rise the question of a possible CLA that is highly suggestive of MEN 2A.

3.8. Conventional Therapy. The treatment of choice for primary MTC, both sporadic or hereditary, is total thyroidectomy with systematic dissection of all lymph nodes of the central compartment. Total thyroidectomy is necessary as MTC is multicentric in 65–90% of patients in MEN 2 and extensive central lymph node dissection has been reported to improve survival and recurrence rates compared to less aggressive procedures [91, 92]. Lymph node dissection of laterocervical compartments is not performed on principle but only when the neck ultrasound suggests the presence of metastatic nodes.

Endoscopic adrenal-sparing surgery has become the method of choice for the surgical therapy of PHEO [93]. In cases with an asynchronous development of PHEO, the adrenal gland without PHEO can be preserved, but the patient must be aware that the probability to repeat the surgical treatment in the near future is very high. The advantage of a monolateral adrenal surgery is the possibility to avoid substitutive therapy until the second surgery will be performed.

The parathyroid glands are frequently found to be enlarged at the time of the thyroidectomy for MTC and should, therefore, be carefully evaluated. The goal in MEN 2 patients with PHPT is to excise the enlarged glands and to leave at least one apparently normal parathyroid gland intact.
If all glands are enlarged, a subtotal parathyroidectomy or total parathyroidectomy with autotransplantation should be performed. In patients with persistent or recurrent PHPT, the long-term oral administration of calcimimetic drugs as cinacalcet to achieve long-term reductions in serum calcium and PTH concentration should be considered.

3.9. Prophylactic or Precocious Thyroidectomy in RET Gene Carrier. Prophylactic thyroidectomy is advised in gene carriers to guarantee a definitive cure in these subjects. Four different risk levels (from A, the lowest, to D the highest) for RET mutations have been suggested by the American Thyroid Association task force, which developed the most recent guidelines for the management of MTC patients [4]. According to these guidelines, these levels of risk, which are related to the clinical aggressiveness of the corresponding MTC, should be taken into consideration when planning surgical treatment. In particular patients with a level D, RET mutation (i.e., Met918Thr) should be treated as soon as possible in the first year of life; patients with level B and C mutations (located in exons 10, 11, 13, 14, and 15) should be operated on before 5 years of age; only for patients with a level A mutation (exon 8 and 5 mutations), total thyroidectomy can be delayed after five years of age or until the CT positivity.

Recently, some evidences in big series of RET gene carriers demonstrated that gene carriers with undetectable levels of basal CT have an almost null risk to have already developed the MTC [90, 94, 95]. Moreover, a serum Ct <30–40 pg/mL is always associated to an intrathyroidal micro-MTC without any evidence of lymph node metastases. Taking into account these observation, Elisei et al. [90] designed a study in which they operated on only RET gene carriers on the basis of basal and stimulated CT. According to their results, the time of surgical treatment could be personalized and safely planned when the stimulated serum CT becomes positive at the annual control, independently from the type of RET mutation and its associated level of risk. Of course, both cysteine RET mutations and older age are risk factors for having an earlier positive result for either basal or Pg-stimulated serum CT. For these reasons, the follow-up controls should be more or less frequent in cysteine or noncysteine RET-mutated gene carriers, respectively. This strategy obviously implies a high compliance of the RET gene carriers to the scheduled followup with the advantage that young children can be treated later, sometime even after the puberty, close to the adulthood.

3.10. Target Therapy for Persistent MTC. Thirty percent of MTC patients, especially in MEN 2B and 2A, are not cured by surgery. They remain affected and can develop, if not already present at the time of the diagnosis, distant metastasis in the lungs, liver, bone and, more rarely, brain. Several studies demonstrated that conventional therapies, such as chemotherapy and radiotherapy, did not determine any clinical benefit [96, 97]. Until few years ago, patients with advanced and progressive MTC were “orphan” of drugs. Recently, developed molecular therapeutics that target the RET pathway have shown very promising activity in clinical trials of patients with advanced MTC [98]. In the majority of cases, the drug is a multitryosine kinase inhibitor (TKI) with the ability to block not only ret butalsoone or more of the vascular endothelial growth factor receptors (VEGF-R) as well as C-MET and/or C-KIT or FLT3 and/or other kinases. Vandetanib has been recently approved both by FDA (Food and Drug Administration) and EMA (European Medical Agency) for the treatment of advanced and progressive MTC. Other TKIs, such as sorafenib, sunitinib, motesanib, lenvatinib, AND cabozantinib, are still under investigation either in official phase II/III clinical trials or in “off-label” studies [99]. Although very promising, further studies and longer followup are needed to better evaluate the clinical benefits in terms of progression-free survival and overall survival as compared to the discomfort determined by the side effects which is not negligible. Among several, the most severe and intolerable side effects are anorexia, weight loss, and fatigue, which are difficult to be controlled. Others, such as hypertension or skin lesions can be managed with standard care procedures. A list of drugs used in ongoing clinical trials is reported in Table 6.

Table 6: Drugs used in ongoing clinical trials for the treatment of advanced MTC and other thyroid tumors.

| Drug          | Molecular target          |
|---------------|---------------------------|
| Axitinib      | VEGFR, PDGFRβ, C. Kit     |
| Gefitinib     | EGFR                      |
| Imatinib      | VEGFR, RET, BCR-ABL       |
| Motesanib     | VEGFR, RET, PDGFRβ, C. Kit|
| Sorafenib     | VEGFR, RET, RET/PTC, BRAF, PDGFRβ, C. Kit |
| Sunitinib     | VEGFR, RET, RET/PTC, PDGFRβ |
| Vandetanib    | VEGFR, RET, RET/PTC, EGFR  |
| XL184         | VEGFR, RET, PDGFRβ        |

4. Conclusions

MEN syndromes are genetic disease transmitted with an autosomal dominant trait. Although rare, they caught the attention of both endocrinologists and geneticists and much information has been collected in the last decades. We know the genetic alterations of both MEN 1 and MEN 2, how they are transmitted, their prevalence, and the relationship between genotype and phenotype. Much is also known about clinical features and possible treatments. Despite all, information still remain to discover the genetic of MEN cases who are orphan of MEN 1 or RET genes germline mutations.

References

[1] J. A. Carney, “Familial multiple endocrine neoplasia syndromes: components, classification, and nomenclature,” *Journal of Internal Medicine*, vol. 243, no. 6, pp. 425–432, 1998.
[2] D. J. Marsh and O. Gimm, “Multiple endocrine neoplasia: types 1 and 2,” *Advances in Oto-Rhino-Laryngology*, vol. 70, pp. 84–90, 2011.
M. L. Brandi, R. F. Gagel, A. Angeli et al., “Consensus guidelines for diagnosis and therapy of MEN type 1 and type 2,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 12, pp. 5658–5671, 2001.

R. T. Kloos, C. Eng, D. B. Evans et al., “Medullary thyroid cancer: management guidelines of the American Thyroid Association,” Thyroid, vol. 19, no. 6, pp. 653–612, 2009.

N. Wohlk, H. Schweizer, Z. Erlic et al., “Multiple endocrine neoplasia type 2,” Best Practice and Research, vol. 24, no. 3, pp. 371–387, 2010.

J. A. Carney, “Familial multiple endocrine neoplasia: the first 100 years,” American Journal of Surgical Pathology, vol. 29, no. 2, pp. 254–274, 2005.

B. Asgharian, Y. J. Chen, N. J. Patronas et al., “Meningiomas may be a component tumor of multiple endocrine neoplasia type 1,” Clinical Cancer Research, vol. 10, no. 3, pp. 869–880, 2004.

B. Asgharian, M. L. Turner, F. Gibril, L. K. Entsuah, J. Serrano, and R. T. Jensen, “Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 11, pp. 5328–5336, 2004.

T. N. Darling, M. C. Skarulis, S. M. Steinberg, S. J. Marx, A. M. Spiegel, and M. Turner, “Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1,” Archives of Dermatology, vol. 133, no. 7, pp. 853–857, 1997.

C. del Pozo, L. García-Pascual, M. Balsells et al., “Parathyroid carcinoma in multiple endocrine neoplasia type 1: case report and review of the literature,” Hormones, vol. 10, no. 4, pp. 326–331, 2011.

F. Cetani, E. Pardi, S. Borsari, and C. Marconcì, “Molecular pathogenesis of primary hyperparathyroidism,” Journal of Endocrinological Investigation, vol. 34, no. 7, supplement, pp. 35–39, 2011.

C. R. C. Pieterman, L. T. Van Hulsteijn, M. Den Heijer et al., “Primary hyperparathyroidism in MEN1 patients: a cohort study with longterm follow-up on preferred surgical procedure and the relation with genotype,” Annals of Surgery, vol. 255, no. 6, pp. 1171–1178, 2012.

C. Eller-Vainicher, I. Chiiodini, C. Battista et al., “Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity,” Journal of Bone and Mineral Research, vol. 24, no. 8, pp. 1404–1410, 2009.

C. Romei, S. Mariotti, L. Fugazzola et al., “Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes,” European Journal of Endocrinology, vol. 163, no. 2, pp. 301–308, 2010.

K. Frank-Raue, W. Höpken, A. Frilling et al., “Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 5, pp. 1780–1783, 1996.

A. Machens, P. Niccoli-Sire, J. Hoegl et al., “Early malignant progression of hereditary medullary thyroid cancer,” New England Journal of Medicine, vol. 349, no. 16, pp. 1517–1525, 2003.

D. H. Schusseheim, M. C. Skarulis, S. K. Agarwal et al., “Multiple endocrine neoplasia type 1: new clinical and basic findings,” Trends in Endocrinology and Metabolism, vol. 12, no. 4, pp. 173–178, 2001.

F. Tonelli, F. Giudici, G. Fratini, and M. L. Brandi, “Pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: review of literature,” Endocrine Practice, vol. 17, supplement 3, pp. 33–40, 2011.

B. Delemaré, “MEN1 and pituitary adenomas,” Annales d’Endocrinologie, vol. 73, no. 2, pp. 59–61, 2012.

L. V. Syro, B. W. Scheithauer, K. Kovacs et al., “Pituitary tumors in patients with MEN1 syndrome,” Clinics, vol. 67, supplement, pp. 43–48, 2012.

S. Schaefer, M. Shipkotko, S. Meyer et al., “Natural course of small adrenal lesions in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study,” European Journal of Endocrinology, vol. 158, no. 5, pp. 699–704, 2008.

R. V. Thakker, “Multiple endocrine neoplasia type 1 (MEN1),” Best Practice & Research, vol. 24, no. 3, pp. 355–370, 2010.

P. Goudet, C. Bonithon-Kopp, A. Murat et al., “Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d’étude des Tumeurs Endocrines,” European Journal of Endocrinology, vol. 165, no. 1, pp. 97–105, 2011.

S. Miedlich, T. Lohmann, U. Schneyer, P. Lamesch, and R. Paschke, “Familial isolated primary hyperparathyroidism—a multiple endocrine neoplasia type 1 variant?” European Journal of Endocrinology, vol. 145, no. 2, pp. 155–160, 2001.

C. Larsson, B. Skogseid, K. Oberg, Y. Nakamura, and M. Nordenskjöld, “Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma,” Nature, vol. 332, no. 6159, pp. 85–87, 1988.

S. C. Chandrasekharappa, S. C. Guru, P. Manickam et al., “Positional cloning of the gene for multiple endocrine neoplasia-type 1,” Science, vol. 276, no. 5311, pp. 404–406, 1997.

A. G. Knudson, “Two genetic hits (more or less) to cancer,” Nature Reviews Cancer, vol. 1, no. 2, pp. 157–162, 2001.

K. Balogh, A. Patócs, L. Hunyady, and K. Rácz, “Menin dynamics and functional insight: take your partners,” Molecular and Cellular Endocrinology, vol. 326, no. 1-2, pp. 80–84, 2010.

T. Wu and X. Hua, “Menin represses tumorigenesis via repressing cell proliferation,” American Journal of Cancer Research, vol. 1, no. 6, pp. 726–39, 2011.

J. Huang, B. Gurung, B. Wan et al., “The same pocket in menin binds both MLL and JUND but has opposite effects on transcription,” Nature, vol. 482, no. 7386, pp. 542–546, 2012.

M. C. Lemos and R. V. Thakker, “Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene,” Nature Reviews Cancer, vol. 11, pp. 97–105, 2011.
gene mutation: clues to a genotype-phenotype correlation,” *Clinics*, vol. 67, supplement, pp. 49–56, 2012.

[36] S.-E. Olufemi, J. S. Green, P. Manickam et al., “Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1(Burin)) in four kindreds from Newfoundland,” *Human Mutation*, vol. 11, no. 4, pp. 264–269, 1998.

[37] C. Kong, S. Ellard, C. JOHNston, and N. R. Farid, “Multiple endocrine neoplasia type 1 Burin from Mauritius: a novel MEN 1 mutation,” *Journal of Endocrinological Investigation*, vol. 24, no. 10, pp. 806–810, 2001.

[38] J. D. M. Lourenco, R. A. Toledo, I. I. Mackowiak et al., “Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation, clinical features, and bone mineral density profile,” *European Journal of Endocrinology*, vol. 159, no. 3, pp. 259–274, 2008.

[39] F. Cetani, E. Pardi, A. Giovannetti et al., “Genetic analysis of the MEN1 gene and HPRT2 locus in two Italian kindreds with familial isolated hyperparathyroidism,” *Clinical Endocrinology*, vol. 56, no. 4, pp. 457–464, 2002.

[40] N. S. Pellegrata, L. Quintanilla-Martinez, H. Siggelkow et al., “Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 42, pp. 15358–15363, 2006.

[41] N. S. Pellegrata, “MENX, *Annales d’Endocrinologie*, vol. 73, no. 2, pp. 65–70, 2012.

[42] S. Molatore and N. S. Pellegrata, “The MENX syndrome and p27: relationships with multiple endocrine neoplasia,” *Progress in Brain Research*, vol. 182, pp. 295–320, 2010.

[43] I. Marinoni and N. S. Pellegrata, “p27Kip1: a new multiple endocrine neoplasia gene?” *Neuroendocrinology*, vol. 93, no. 1, pp. 19–28, 2011.

[44] N. Nilubol, L. Weinstein, W. F. Simonetti et al., “Preoperative localizing studies for initial parathyroidectomy in MEN1 syndrome: is there any benefit?” *World Journal of Surgery*, vol. 36, no. 6, pp. 1368–1374, 2012.

[45] B. Verges, F. Bourelle, P. Goudet et al., “Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study,” *Journal of Clinical Endocrinology and Metabolism*, vol. 87, no. 2, pp. 457–465, 2002.

[46] C. Barbe, A. Murat, B. Dupas et al., “Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1,” *Digestive and Liver Disease*, vol. 44, no. 3, pp. 228–234, 2012.

[47] R. V. Thakker, P. J. Newey, G. V. Wall et al., “Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1),” *Journal of Clinical Endocrinology and Metabolism*, vol. 97, no. 9, pp. 2980–3011, 2012.

[48] G. A. Stratakis, D. H. Schussheim, S. M. Freedman et al., “Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1,” *Journal of Clinical Endocrinology and Metabolism*, vol. 85, no. 12, pp. 4776–4780, 2000.

[49] T. Carling and R. Udelsman, “Parathyroid surgery in familial hyperparathyroid disorders,” *Journal of Internal Medicine*, vol. 257, no. 1, pp. 27–37, 2005.

[50] J. Waldmann, C. L. López, P. Langer, M. Rothmund, and D. K. Bartsch, “Surgery for multiple endocrine neoplasia type 1-associated primary hyperparathyroidism,” *British Journal of Surgery*, vol. 97, no. 10, pp. 1528–1534, 2010.

[51] D. M. Elaraj, M. C. Skarulis, S. K. Libutti et al., “Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1,” *Surgery*, vol. 134, no. 6, pp. 858–865, 2003.

[52] F. Tonelli, S. Pinii, M. Tommassi et al., “Intraoperative parathormone measurement in patients with multiple endocrine neoplasia type 1 syndrome and hyperparathyroidism,” *World Journal of Surgery*, vol. 24, no. 5, pp. 556–563, 2000.

[53] F. Tonelli, T. Marucci, G. Fratini, M. S. Tommassi, A. Falchetti, and M. L. Brandi, “Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1?” *Annals of Surgery*, vol. 246, no. 6, pp. 1075–1082, 2007.

[54] P. V. Dickson, T. A. Rich, Y. Xing et al., “Achieving eugastrinemia in MEN1 patients: both duodenal inspection and formal lymph node dissection are important,” *Surgery*, vol. 150, no. 6, pp. 1143–1152, 2011.

[55] F. Triponez, D. Dosseh, P. Goudet et al., “Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas,” *Annals of Surgery*, vol. 243, no. 2, pp. 265–272, 2006.

[56] K. Öberg. “Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches,” *Current Opinion in Oncology*, vol. 24, no. 4, pp. 433–440, 2012.

[57] A. Germain, M. Klein, and L. Brunaud, “Surgical management of adrenal tumors,” *Journal of Visceral Surgery*, vol. 148, no. 4, pp. e250–e261, 2011.

[58] P. Goudet, A. Murat, C. Bineguet et al., “Risk factors and causes of death in men1 disease. a gte (groupe d’étude des tumeurs endocrines) cohort study among 758 patients,” *World Journal of Surgery*, vol. 34, no. 2, pp. 249–255, 2010.

[59] H. P. H. Neumann, A. Vortmeyer, D. Schmidt et al., “Brief report: evidence of MEN-2 in the original description of classic pheochromocytoma,” *New England Journal of Medicine*, vol. 357, no. 13, pp. 1311–1315, 2007.

[60] J. H. Sipple, “Multiple endocrine neoplasia type 2 syndromes: historical perspectives,” *Henry Ford Hospital Medical Journal*, vol. 32, no. 4, pp. 219–222, 1984.

[61] H. R. Keiser, M. A. Beaver, I. Doppman, S. Wells, and L. M. Buja, “Sipple’s syndrome: medullary thyroid carcinoma, pheochromocytoma, and parathyroid disease. Studies in a large family. NIH conference,” *Annals of Internal Medicine*, vol. 78, no. 4, pp. 561–579, 1973.

[62] A. L. Steiner, A. D. Goodman, and S. R. Powers, “Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing’s disease: multiple endocrine neoplasia type 2,” *Medicine*, vol. 47, no. 5, pp. 371–409, 1968.

[63] J. R. Howe, J. A. Norton, S. A. Wells, C. Proye, G. B. Talpos, and S. E. Carty, “Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up,” *Surgery*, vol. 114, no. 6, pp. 1070–1077, 1993.

[64] W. B. Inabnet, P. Caraglano, D. Pertsemidis et al., “Pheochromocytoma: inherited associations, bilaterality, and cortex preservation,” *Surgery*, vol. 128, no. 6, pp. 1007–1012, 2000.

[65] J. M. Rodríguez, M. Balsalobre, J. L. Ponce et al., “Pheochromocytoma in MEN 2A syndrome. Study of 54 patients,” *World Journal of Surgery*, vol. 32, no. 11, pp. 2520–2526, 2008.

[66] M. Verdý, A. M. Weber, and C. C. Roy, “Hirschsprung’s disease in a family with multiple endocrine neoplasia type 2,” *Journal of Pediatric Gastroenterology and Nutrition*, vol. 1, no. 4, pp. 603–607, 1982.

[67] M. B. Verdý, M. Cadotte, and W. Schurch, “A French Canadian family with multiple endocrine neoplasia type 2 syndromes,”
C. Eng, D. Clayton, I. Schuffenecker et al., “The relationship between specific ret proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: international RET mutation consortium analysis,” Journal of the American Medical Association, vol. 276, no. 19, pp. 1575–1579, 1996.

D. T. Donovan, M. L. Levy, B. R. Alford, T. Wheeler, and J. A. Tschen, “Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis,” Annals of Internal Medicine, vol. 111, no. 10, pp. 802–806, 1989.

W. J. Cunliffe, P. Hudson, I. J. Fulthorpe et al., “A calcitonin-secreting medullary thyroid carcinoma associated with mucosal neuromas, marfanoid features, myopathy and pigmentation,” The American Journal of Medicine, vol. 48, no. 1, pp. 120–126, 1970.

M. Brauckhoff, A. Machens, S. Hess et al., “Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: an exploratory analysis,” Surgery, vol. 144, no. 6, pp. 1044–1051, 2008.

J. R. Farndon, G. S. Leight, and W. G. Dilley, “Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity,” British Journal of Surgery, vol. 73, no. 4, pp. 278–281, 1986.

R. Elisei, C. Romei, B. Cosci et al., “Brief report: RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 12, pp. 4725–4729, 2007.

P. Niccoli-Sire, A. Murat, V. Rohmer et al., “Familial medullary thyroid carcinoma with noncysteine RET mutations: phenotype-genotype relationship in a large series of patients,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 8, pp. 3746–3753, 2001.

C. Romei, B. Cosci, G. Renzini et al., “RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC),” Clinical Endocrinology, vol. 74, no. 2, pp. 241–247, 2011.

M. S. Cohen and J. F. Moley, “Surgical treatment of medullary thyroid carcinoma,” Journal of Internal Medicine, vol. 253, no. 6, pp. 616–626, 2003.

H. Domis-Keller, S. Dou, D. Chi et al., “Mutations in the RET proto-oncogene are associated with MEN 2A and FMT,” Human Molecular Genetics, vol. 2, no. 7, pp. 851–856, 1993.

L. M. Mulligan, J. B. J. Kwok, C. S. Healey et al., “Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A,” Nature, vol. 363, no. 6428, pp. 458–460, 1993.

C. Eng, D. P. Smith, L. M. Mulligan et al., “Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours,” Human Molecular Genetics, vol. 3, no. 2, pp. 237–241, 1994.

M. F. Erdogan, A. Gürsoy, G. Özgen et al., “Ret proto-oncogene mutations in apparently sporadic Turkish medullary thyroid carcinoma patients: Turkmen study,” Journal of Endocrinological Investigation, vol. 28, no. 9, pp. 806–809, 2005.

C. Eng, L. M. Mulligan, D. P. Smith et al., “Low frequency of germline mutations in the RET protooncogene in patients with apparently sporadic medullary thyroid carcinoma,” Clinical Endocrinology, vol. 43, no. 1, pp. 123–127, 1995.

G. Orgiana, G. Pinna, A. Camedda et al., “A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 10, pp. 4810–4816, 2004.

B. Cosci, A. Vivaldi, C. Romei et al., “In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer,” Endocrine-Related Cancer, vol. 16, no. 5, pp. 603–612, 2011.

J. R. Hansford and L. M. Mulligan, “Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis,” Journal of Medical Genetics, vol. 37, no. 11, pp. 817–827, 2000.

K. M. Zbuk and C. Eng, “Cancer phenomics: RET and PTEN as illustrative models,” Nature Reviews Cancer, vol. 7, no. 1, pp. 35–45, 2007.

A. Miyauchi, H. Futami, N. Hai et al., “Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation,” Japanese Journal of Cancer Research, vol. 90, no. 1, pp. 1–5, 1999.

F. H. Menko, R. B. Van Der Luijt, I. A. J. De Valk et al., “Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 1, pp. 393–397, 2002.

K. Frank-Raue, S. Rondot, and F. Raue, “Molecular genetics and phenomics of RET mutations: impact on prognosis of MTC,” Molecular and Cellular Endocrinology, vol. 322, no. 1–2, pp. 2–7, 2010.

R. Elisei, C. Romei, G. Renzini et al., “The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 Years experience at one single center,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 2, pp. 426–435, 2012.

A. Machens, S. Hauptmann, and H. Drale, “Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer,” World Journal of Surgery, vol. 31, no. 10, pp. 1960–1965, 2007.

C. F. Russell, J. A. Van Heerden, and G. W. Sizemore, “The surgical management of medullary thyroid carcinoma,” Annals of Surgery, vol. 197, no. 1, pp. 42–48, 1983.

M. K. Walz and P. F. Alesina, “Single access retroperitoneoscopic adrenalectomy (SARA)-one step beyond in endocrine surgery,” Langenbeck’s Archives of Surgery, vol. 394, no. 3, pp. 447–450, 2009.

G. S. K. Lau, B. H. H. Lang, C. Y. Lo et al., “Prophylactic thyroidectomy in ethnic Chinese patients with multiple endocrine neoplasia type 2A syndrome after the introduction of genetic testing,” Hong Kong Medical Journal, vol. 15, no. 5, pp. 326–331, 2009.

V. Rohmer, G. Vidal-Trecan, A. Bourdelot et al., “Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Franc¸ais d’Etude des Tumeurs Endocrines,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 3, pp. E509–E518, 2011.
[96] S. I. Sherman, “Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 5, pp. 1493–1499, 2009.

[97] S. I. Sherman, “Cytotoxic chemotherapy for differentiated thyroid carcinoma,” Clinical Oncology, vol. 22, no. 6, pp. 464–468, 2010.

[98] S. A. Wells Jr., B. G. Robinson, R. F. Gagel et al., “Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial,” Journal of Clinical Oncology, vol. 30, no. 2, pp. 134–141, 2012.

[99] M. L. Gild, M. Bullock, B. G. Robinson, and R. Clifton-Bligh, “Multikinase inhibitors: a new option for the treatment of thyroid cancer,” Nature Reviews Endocrinology, vol. 7, no. 10, pp. 617–624, 2011.